Navigation Links
Pest Control research Leads to Pain Control Discovery

Researchers have claimed that studies that were being conducted towards pest control have lead to the discovery of pain control. //

Researchers from the University of California, have stated that the newly discovered enzyme inhibitor, which earlier had been identified by researchers who were initially looking for biological pest controls, might actually lead to pain relief for people suffering from arthritis and other inflammatory diseases. It has been reported that a noted inflammatory disease expert has acknowledged the discovery as the most important discovery in inflammation in more than a decade, and was of the opinion that it might also reduce side effects associated with the painkiller, Vioxx.

Lead author Kara Schmelzer, a post-doctoral researcher in principal investigator Bruce Hammock's lab, tested the novel compounds on rodents and found them to be as potent at a low-dose as Vioxx and Celebrex, but without the changes in blood chemistry linked to heart attacks. Vioxx and Celebrex belong to a class of drugs known as Cox-2 inhibitors. The enzyme targeted by the newly discovered inhibitors is also found in humans. (Enzymes are proteins that speed up chemical reactions.)

'The reason this is so exciting is that this is a novel way to reduce inflammation, with a combination therapy,' Schmelzer said. 'We're going after a new enzyme target, not going after the Cox-2 inhibitors.'

Their research is reported in a paper entitled 'Enhancement of Antinociception by Co administration of Nonsteroidal Anti-Inflammatory Drugs and Soluble Epoxide Hydrolase Inhibitors,' published in the current edition of Proceedings of the National Academy of Sciences.

'Our laboratory was initially interested in regulating the development of insect larvae,' said Hammock, a distinguished professor of entomology and member of the National Academy of Sciences.” The discovery switched the focus of the research from ‘pest control to pain control’.

M. Eric Gershwin, chief of the Division of Rheumatology, Allergy and Clinical Immunology at the UC Davis School of Medicine and a distinguished professor of medicine, called the discovery 'the most important discovery in inflammation in more than a decade.' Gershwin, who was not affiliated with this study, is noted for his research on rheumatoid arthritis and other inflammatory diseases. His lab investigates the mechanisms leading to immunological alterations and autoimmunity.

As of 2004, physicians prescribed anti-inflammatory medication for more than 73 million patients. But many of the people suffer from pharmacological properties or side effects of the medications. Merck, the pharmaceutical company that manufactured and marketed Vioxx, a Cox-2 selective nonsteroidal anti-inflammatory drug (NSAID), voluntarily pulled the pain killer from the market in September 2004 due to safety concerns. A 12-month study, published in 2000, showed a four-fold increased risk of heart attacks. Merck hopes to replace it with another medication, Acoxia.

However, the class of drugs benefits millions of sufferers from inflammation and pain, Hammock said. The UC Davis study may mean a solution to the dilemma of whether to use the drugs.

'Combination therapies have long been used to treat inflammation while reducing side effects,' Schmelzer wrote. She said the present study was designed to evaluate the therapeutic potential of combination treatment with NSAIDs and enzyme inhibitors (a previously undescribed soluble epoxide hydrolase inhibitor or sEHIs) in lipopolysaccharide (LPS)-challenged mice.

'We used LPS as an inflammatory agent, which is a component of some bacterial cell walls,' said, co-author Steven Jinks. His laboratory examined the effects of these compounds in rodent inflammatory pain behavior models. 'Inflammatory mediators sensitize pain receptors and cause the animal to withdraw more quickly from a nox ious stimulus, an indication of 'hyperalgesia' or heightened response to a painful stimulus.' The sEH inhibitors reverse hyperalgesia and bring their withdrawal reaction back into the normal range.

Hammock said 'these sEHIs are of similar or greater potency in reducing inflammation in rodents to Vioxx, but also when combined with Vioxx can dramatically reduce the concentrations of the Cox 2 inhibitor needed,' Hammock said.

'The combination of Vioxx with the new sEHIs shifts blood chemistry toward the normal condition which may reduce the tendency toward blood clots,' said UC Davis scientist Bora Inceoglu, a post-doctoral researcher and member of the research team.
VK
'"/>




Related medicine news :

1. FDA Approves Birth Control Skin Patch
2. Control of inflammation
3. New Birth Control Pills increase the stroke risk
4. Control of anger disorder connected to Brain Dysfunction
5. WHO Declares Vietnam First Country to Control SARS
6. The Importance Of “ Good ”Control Of Diabetes During Pregnanc
7. Controlling Asthma during Pregnancy
8. Effective Control Of Blood Sugar Levels
9. Controlling Allergies Before They Start
10. Diabetics Can Now Be Able To Control Both Blood Sugar And Their Weight
11. Better Control Of Sugar Levels
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... , ... December 06, 2016 ... ... on Friday, November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. ... eye-catching label design. Featuring one of the world’s most powerful antioxidants, molecular ...
(Date:12/6/2016)... ... December 06, 2016 , ... TopConsumerReviews.com recently gave a ... Scooters . , Mobility Scooters give freedom to people who need help getting around. ... may be facing a long period of rehabilitation after an illness or accident. There ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is a ... lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO of ... create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... GA (PRWEB) , ... December ... ... technology and security executive networking and relationship-marketing firm, announced today that nominations ... the 2017 Information Security Executive® (ISE®) Central Awards. , Awards include the ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education ... Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on ... “We are honored to have Amy E. Herman present at this year’s conference, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016   Lexicon Pharmaceuticals, ... results today from a Phase 2 clinical study of ... Lexicon in collaboration with JDRF, the leading global organization ... of this Phase 2 clinical trial, which randomized a ... of a once-daily 400 mg dose of sotagliflozin compared ...
(Date:12/5/2016)... , December 5, 2016 According to ... Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), ... by MarketsandMarkets, the market is projected to reach USD 779.8 Million ... CAGR of 13.5% during the forecast period of 2016 to 2021. ... ...
(Date:12/5/2016)... PORTLAND, Oregon and PUNE, India ... a new report by Allied Market Research, titled, "Global Cancer ... the global revenue of cancer biomarkers market is projected to ... at a CAGR of 13.3% from 2016 to 2022. Omic ... share in 2015 and is expected to maintain its dominance ...
Breaking Medicine Technology: